{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T20:21:24Z","timestamp":1783542084968,"version":"3.55.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.neulet.2018.04.039","type":"journal-article","created":{"date-parts":[[2018,4,22]],"date-time":"2018-04-22T17:56:57Z","timestamp":1524419817000},"page":"133562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Leveraging genetics to enhance the efficacy of PTSD pharmacotherapies"],"prefix":"10.1016","volume":"726","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-8563","authenticated-orcid":false,"given":"Mark W.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2018.04.039_bib0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/archpsyc.1995.03950240066012","article-title":"Posttraumatic stress disorder in the national comorbidity survey","volume":"52","author":"Kessler","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0010","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0015","series-title":"Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adult","year":"2017"},{"key":"10.1016\/j.neulet.2018.04.039_bib0020","series-title":"Guidelines for the Management of Conditions Specifically Related to Stress","year":"2013"},{"key":"10.1016\/j.neulet.2018.04.039_bib0025","series-title":"VA\/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder","year":"2017"},{"key":"10.1016\/j.neulet.2018.04.039_bib0030","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.biopsych.2017.03.007","article-title":"It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD psychopharmacology working group","volume":"82","author":"Krystal","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1192\/bjp.bp.114.148551","article-title":"Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis","volume":"206","author":"Hoskins","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0040","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/da.22511","article-title":"Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments","volume":"33","author":"Lee","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neulet.2018.04.039_bib0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4088\/JCP.11m07311","article-title":"Prescribing trends in veterans with posttraumatic stress disorder","volume":"73","author":"Bernardy","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0050","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1176\/appi.ps.201300176","article-title":"Implementation of evidence-based psychotherapies for posttraumatic stress disorder in VA specialty clinics","volume":"65","author":"Watts","year":"2014","journal-title":"Psychiatr. Serv."},{"issue":"May (3)","key":"10.1016\/j.neulet.2018.04.039_bib0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10488-017-0828-8","article-title":"Documentation of evidence-based psychotherapy and care quality for ptsd in the department of veterans affairs","volume":"45","author":"Sripada","year":"2018","journal-title":"Adm. Policy Mental Health"},{"key":"10.1016\/j.neulet.2018.04.039_bib0060","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/archpsyc.63.10.1158","article-title":"Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial","volume":"63","author":"Davidson","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0065","first-page":"75","article-title":"The development of a clinician-administered PTSD scale","volume":"8","author":"Blake","year":"1995","journal-title":"J. Trauma. Stress"},{"key":"10.1016\/j.neulet.2018.04.039_bib0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1176\/appi.ps.201200217","article-title":"Aligning clinical practice to PTSD treatment guidelines: medication prescribing by provider type","volume":"64","author":"Abrams","year":"2013","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.neulet.2018.04.039_bib0075","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.janxdis.2010.11.010","article-title":"Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"25","author":"Pietrzak","year":"2011","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.neulet.2018.04.039_bib0080","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.biopsych.2007.04.036","article-title":"Differential etiology of posttraumatic stress disorder with conduct disorder and major depression in male veterans","volume":"62","author":"Fu","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0085","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/npp.2015.266","article-title":"The genetics of stress-related disorders: PTSD, depression, and anxiety disorders","volume":"41","author":"Smoller","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neulet.2018.04.039_bib0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/gbb.12104","article-title":"Gene-environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism","volume":"13","author":"Zannas","year":"2014","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neulet.2018.04.039_bib0095","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neulet.2018.04.039_bib0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neulet.2018.04.039_bib0105","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u2013an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neulet.2018.04.039_bib0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/11586630-000000000-00000","article-title":"Pharmacokinetics of venlafaxine extended release 75\u202fmg and desvenlafaxine 50\u202fmg in healthy CYP2D6 extensive and poor metabolizers: a randomized open-label, two-period, parallel-group, crossover study","volume":"31","author":"Nichols","year":"2011","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.neulet.2018.04.039_bib0115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ajmg.b.32309","article-title":"ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis","volume":"168","author":"Breitenstein","year":"2015","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.neulet.2018.04.039_bib0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpsychires.2015.11.010","article-title":"Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: results from a randomized clinical study","volume":"73","author":"Breitenstein","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neulet.2018.04.039_bib0125","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/appi.ajp.2015.14050680","article-title":"ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial","volume":"172","author":"Schatzberg","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0130","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neuroscience.2007.09.017","article-title":"Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect","volume":"150","author":"Shishkina","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neulet.2018.04.039_bib0135","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.biopsych.2007.01.015","article-title":"Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons","volume":"62","author":"Scheuch","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0140","first-page":"2166","article-title":"Serotonin and the brain\u2019s rich club-association between molecular genetic variation on the TPH2 gene and the structural connectome","volume":"27","author":"Markett","year":"2017","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neulet.2018.04.039_bib0145","doi-asserted-by":"crossref","first-page":"e36721","DOI":"10.1371\/journal.pone.0036721","article-title":"TPH2 gene polymorphisms and major depression\u2013a meta-analysis","volume":"7","author":"Gao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2018.04.039_bib0150","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1046\/j.1471-4159.1996.66062621.x","article-title":"Allelic variation of human serotonin transporter gene expression","volume":"66","author":"Heils","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2018.04.039_bib0155","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1176\/appi.ajp.2010.09101452","article-title":"Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits","volume":"167","author":"Caspi","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0160","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jts.21855","article-title":"The 5-HTTLPR polymorphism and posttraumatic stress disorder: a meta-analysis","volume":"26","author":"Gressier","year":"2013","journal-title":"J. Trauma. Stress"},{"key":"10.1016\/j.neulet.2018.04.039_bib0165","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/phar.1978","article-title":"Serotonin transporter gene polymorphisms and selective serotonin reuptake inhibitor tolerability: review of pharmacogenetic evidence","volume":"37","author":"Zhu","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neulet.2018.04.039_bib0170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euroneuro.2011.10.003","article-title":"Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy","volume":"22","author":"Porcelli","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2018.04.039_bib0175","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mp.2011.68","article-title":"Identification of tag haplotypes for 5HTTLPR for different genome-wide SNP platforms","volume":"16","author":"Vinkhuyzen","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0180","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/sj.npp.1300057","article-title":"Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders","volume":"28","author":"Marek","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neulet.2018.04.039_bib0185","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1073858404267382","article-title":"5-HT1A receptors, gene repression, and depression: guilt by association","volume":"10","author":"Albert","year":"2004","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neulet.2018.04.039_bib0190","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.euroneuro.2015.12.039","article-title":"The 5-HT1A receptor in major depressive disorder","volume":"26","author":"Kaufman","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2018.04.039_bib0195","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1038\/tp.2015.226","article-title":"The functional serotonin 1a receptor promoter polymorphism, rs6295, is associated with psychiatric illness and differences in transcription","volume":"6","author":"Donaldson","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0200","doi-asserted-by":"crossref","first-page":"e1150","DOI":"10.1038\/tp.2017.108","article-title":"The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning","volume":"7","author":"Kautzky","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0205","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pnpbp.2013.05.011","article-title":"Pharmacogenetics in major depression: a comprehensive meta-analysis","volume":"45","author":"Niitsu","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/mp.2008.116","article-title":"Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder","volume":"15","author":"Kato","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0215","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1176\/appi.ajp.2007.06111790","article-title":"Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort","volume":"164","author":"Paddock","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0220","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.mp.4001502","article-title":"Investigation of serotonin-related genes in antidepressant response","volume":"9","author":"Peters","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0225","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jad.2014.06.012","article-title":"Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis","volume":"168","author":"Lin","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neulet.2018.04.039_bib0230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1017\/S1461145709991027","article-title":"Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB","volume":"13","author":"Laje","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2018.04.039_bib0235","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s10072-014-1970-7","article-title":"Association of HTR2A T102C and A-1438G polymorphisms with susceptibility to major depressive disorder: a meta-analysis","volume":"35","author":"Zhao","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neulet.2018.04.039_bib0240","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/mp.2012.76","article-title":"Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies","volume":"18","author":"Taylor","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0245","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00439-013-1388-y","article-title":"Association of the HTR2A gene with alcohol and heroin abuse","volume":"133","author":"Cao","year":"2014","journal-title":"Hum. Genet."},{"key":"10.1016\/j.neulet.2018.04.039_bib0250","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/mp.2015.138","article-title":"Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways","volume":"21","author":"Howe","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0255","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.neuropharm.2012.06.007","article-title":"Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL\/6J mice","volume":"64","author":"Zhang","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neulet.2018.04.039_bib0260","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4236\/jbbs.2012.24053","article-title":"5-HT2A receptor activation normalizes exaggerated fear behavior in p-chlorophenylalanine (PCPA)-treated rats","volume":"2","author":"Hughes","year":"2012","journal-title":"J. Behav. Brain Sci."},{"key":"10.1016\/j.neulet.2018.04.039_bib0265","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fnins.2016.00299","article-title":"5-HT2A gene variants moderate the association between PTSD and reduced default mode network connectivity","volume":"10","author":"Miller","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neulet.2018.04.039_bib0270","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/S0028-3908(98)00141-5","article-title":"Transport of brain-derived neurotrophic factor across the blood-brain barrier","volume":"37","author":"Pan","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neulet.2018.04.039_bib0275","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mp.2013.105","article-title":"Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N\u202f=\u202f9484)","volume":"19","author":"Molendijk","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0280","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/mp.2017.61","article-title":"Neuronal plasticity and neurotrophic factors in drug responses","volume":"22","author":"Castren","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0285","doi-asserted-by":"crossref","first-page":"e0172270","DOI":"10.1371\/journal.pone.0172270","article-title":"Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression","volume":"12","author":"C. Zhou","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2018.04.039_bib0290","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0092-8674(03)00035-7","article-title":"The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function","volume":"112","author":"Egan","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.neulet.2018.04.039_bib0295","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jad.2017.10.024","article-title":"BDNF Val66Met polymorphism, life stress and depression: a meta-analysis of gene-environment interaction","volume":"227","author":"Zhao","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neulet.2018.04.039_bib0300","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/appy.12148","article-title":"Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis","volume":"6","author":"Yan","year":"2014","journal-title":"Asia Pac. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0305","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/mp.2012.180","article-title":"PTSD risk is associated with BDNF Val66Met and BDNF overexpression","volume":"19","author":"Zhang","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0310","doi-asserted-by":"crossref","first-page":"6979435","DOI":"10.1155\/2016\/6979435","article-title":"A case-control study and meta-analysis reveal BDNF Val66Met is a possible risk factor for PTSD","volume":"2016","author":"Bruenig","year":"2016","journal-title":"Neural Plast."},{"key":"10.1016\/j.neulet.2018.04.039_bib0315","doi-asserted-by":"crossref","first-page":"4569698","DOI":"10.1155\/2017\/4569698","article-title":"Brain-derived neurotropic factor Val66Met polymorphism and posttraumatic stress disorder among survivors of the 1998 dongting lake flood in China","volume":"2017","author":"Dai","year":"2017","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.neulet.2018.04.039_bib0320","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1523\/JNEUROSCI.23-01-00349.2003","article-title":"Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects","volume":"23","author":"Saarelainen","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2018.04.039_bib0325","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.biopsych.2010.11.019","article-title":"The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognition-environment interactions","volume":"69","author":"Juhasz","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0330","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/archgenpsychiatry.2009.201","article-title":"Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients","volume":"67","author":"Kohli","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0335","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1038\/tp.2016.20","article-title":"A. Papassotiropoulos, a common NTRK2 variant is associated with emotional arousal and brain white-matter integrity in healthy young subjects","volume":"6","author":"Spalek","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0340","doi-asserted-by":"crossref","first-page":"e00360","DOI":"10.1002\/brb3.360","article-title":"Genetic association of the transcription of neuroplasticity-related genes and variation in stress-coping style","volume":"5","author":"Aizawa","year":"2015","journal-title":"Brain Behav."},{"key":"10.1016\/j.neulet.2018.04.039_bib0345","doi-asserted-by":"crossref","first-page":"e64947","DOI":"10.1371\/journal.pone.0064947","article-title":"Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach","volume":"8","author":"Hennings","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl. 1","key":"10.1016\/j.neulet.2018.04.039_bib0350","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/j.psyneuen.2009.05.021","article-title":"The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders","volume":"34","author":"Binder","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neulet.2018.04.039_bib0355","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/bies.201600050","article-title":"FK506 binding protein 51 integrates pathways of adaptation: FKBP51 shapes the reactivity to environmental change","volume":"38","author":"Rein","year":"2016","journal-title":"Bioessays"},{"key":"10.1016\/j.neulet.2018.04.039_bib0360","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.pnpbp.2017.10.005","article-title":"Pleiotropic genes in psychiatry: calcium channels and the stress-related FKBP5 gene in antidepressant resistance","volume":"81","author":"Fabbri","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0365","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/ng1479","article-title":"Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment","volume":"36","author":"Binder","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neulet.2018.04.039_bib0370","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.299.11.1291","article-title":"Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults","volume":"299","author":"Binder","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.neulet.2018.04.039_bib0375","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jad.2017.08.066","article-title":"Interaction between early-life stress and FKBP5 gene variants in major depressive disorder and post-traumatic stress disorder: a systematic review and meta-analysis","volume":"225","author":"Wang","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neulet.2018.04.039_bib0380","doi-asserted-by":"crossref","first-page":"e1001755","DOI":"10.1371\/journal.pmed.1001755","article-title":"Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans","volume":"11","author":"Gassen","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.neulet.2018.04.039_bib0385","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/mp.2015.38","article-title":"FKBP51 inhibits GSK3beta and augments the effects of distinct psychotropic medications","volume":"21","author":"Gassen","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0390","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/npp.2012.191","article-title":"Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline \u2018predictors\u2019 and longitudinal \u2018targets\u2019","volume":"38","author":"Cattaneo","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neulet.2018.04.039_bib0395","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/FPC.0b013e32835dc133","article-title":"FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder","volume":"23","author":"Ellsworth","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.neulet.2018.04.039_bib0400","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.biopsych.2012.10.030","article-title":"Contribution of common genetic variants to antidepressant response","volume":"73","author":"Tansey","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0405","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pnpbp.2017.01.011","article-title":"Pharmacogenetics of antidepressant response: a polygenic approach","volume":"75","author":"Garcia-Gonzalez","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0410","doi-asserted-by":"crossref","first-page":"150","DOI":"10.9758\/cpn.2015.13.2.150","article-title":"Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.neulet.2018.04.039_bib0415","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial","volume":"17","author":"Perez","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neulet.2018.04.039_bib0420","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.biopsych.2016.12.001","article-title":"A new hope for biological insights into depression","volume":"81","author":"Hyman","year":"2017","journal-title":"Biol. Psychiatry"}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018303021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018303021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:32:46Z","timestamp":1759609966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394018303021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":84,"alternative-id":["S0304394018303021"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2018.04.039","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging genetics to enhance the efficacy of PTSD pharmacotherapies","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2018.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"133562"}}